

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 10/663,048 09/16/2003 LAIM3006/REF 2552 Ming-Derg Lai 06/28/2005 **EXAMINER** 23364 7590 **BACON & THOMAS, PLLC** GUZO, DAVID **625 SLATERS LANE** ART UNIT PAPER NUMBER FOURTH FLOOR ALEXANDRIA, VA 22314 1636

DATE MAILED: 06/28/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

•	1	Application No.	Applicant(s)	
	•	10/663,048	LAI ET AL.	
Office Action Summary		Examiner	Art Unit	
		David Guzo	1636	
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply				
A SHORTENED STATUTORY PER THE MAILING DATE OF THIS COM - Extensions of time may be available under the profiter SIX (6) MONTHS from the mailing date of the period for reply specified above is less than if NO period for reply is specified above, the maximum failure to reply within the set or extended period Any reply received by the Office later than three earned patent term adjustment. See 37 CFR 1.7	IMUNICATION. ovisions of 37 CFR 1.136(is communication. thirty (30) days, a reply wi imum statutory period will for reply will, by statute, ca months after the mailing de	a). In no event, however, may a reply be tim ithin the statutory minimum of thirty (30) days apply and will expire SIX (6) MONTHS from to tuse the application to become ABANDONED	ely filed will be considered timely. he mailing date of this communication. 0 (35 U.S.C. § 133).	
Status				
1) Responsive to communication	(s) filed on <u>16 Sep</u>	<u>tember 2003</u> .		
2a) This action is FINAL .	2b)∐ This a	ction is non-final.		
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.				
Disposition of Claims				
4) Claim(s) 1-36 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 1-36 are subject to restriction and/or election requirement.				
Application Papers				
9) The specification is objected to by the Examiner.				
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.				
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).				
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.				
Priority under 35 U.S.C. § 119				
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 				
Attachment(s)				
1) Notice of References Cited (PTO-892)		4) Interview Summary (
Notice of Draftsperson's Patent Drawing Re Information Disclosure Statement(s) (PTO-Paper No(s)/Mail Date		Paper No(s)/Mail Da 5) Notice of Informal Pa 6) Other:	te atent Application (PTO-152)	

MC

Application/Control Number: 10/663,048 Page 2

Art Unit: 1636

Election/Restriction

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-18, drawn to a DNA vaccine containing a tumor-associated gene and a cytokine gene as well as a suitable promoter or translation regulatory sequence in a vector, classified in class 514, subclass 44.
- II. Claims 19-36, drawn to a method for preparing a DNA vaccine containing a tumor-associated gene and a cytokine gene, comprising designing a primer sequence containing a proper restriction site, using PCR to amplify and isolate said tumor-associated gene and cytokine gene respectively, and using ligase to co-incorporate respectively the tumor-associated gene and cytokine gene into a vector having a suitable promoter or translation regulatory sequence, classified in class 435, subclass 91.4.

The inventions are distinct, each from the other because of the following reasons:

Inventions I and II are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)).

In the instant case the DNA vaccine vector can be made by separately cloning the tumor-associated gene and the cytokine gene into a preexisting vector by simply ligating the genes separately into suitable restriction sites in the vector.

Application/Control Number: 10/663,048

Art Unit: 1636

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

The examiner has required restriction between product and process claims.

Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

Application/Control Number: 10/663,048

Art Unit: 1636

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of In re Ochiai, In re Brouwer and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy. Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David Guzo, Ph.D., whose telephone number is (571) 272-0767. The examiner can normally be reached on Monday-Thursday from 8:00 AM to 5:30 PM. The examiner can also be reached on alternate Fridays.

Art Unit: 1636

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Irem Yucel, Ph.D., can be reached on (571) 272-0781. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

David Guzo June 24, 2005

PRIMARY EXAMINER

Page 5